Press Releases

BioCina Chief Executive Officer, Mark W. Womack BioCina Chief Executive Officer, Mark W. Womack [ADELAIDE, SOUTH AUSTRALIA and PERTH, WESTERN AUSTRALIA, January 14, 2025] – Global Contract Development and Manufacturing Organizations (CDMOs) BioCina and NovaCina announced a strategic merger that will create a powerful brand in biopharmaceutical and small molecule contract manufacturing. The combined company, […]

Exciting news from NovaCina! We’ve installed and qualified a new Cytiva SA25 GMP isolator filling line to support small- and medium-batch sizes for all clinical phases—vials, syringes and cartridges. Since acquiring the manufacturing plant from Pfizer in April 2023, we have invested heavily into the site growing diverse CDMO capability and team. And now we’ve

Adelaide, South Australia, October 10, 2024/– BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced a new partnership with Centivax, Inc., for a project involving cell line development, cell banking and plasmid DNA manufacture. Centivax is developing Cent-Flu, a universal influenza vaccine, consisting of a proprietary multivalent mixture of 22

Adelaide, South Australia, September 25, 2024/ — BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced a new partnership with drug developer EnGeneIC Pty Ltd., for a project including technology transfer, process scale-up and GMP batch manufacture of EnGeneIC’s proprietary ‘EnGeneIC Dream Vector’ (EDV™) nanocells.    EnGeneIC’s mission is to

BioCina Acquires the Exclusive CDMO Rights for Leading-Edge Minicircle DNA Technology Platform from CelluTx Adelaide, South Australia, June 3, 2024/– BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced the exclusive rights to utilize CelluTx’s Recombination Based Plasmid System (RBPS) technology with BioCina’s CDMO clients. RBPS is a cutting-edge technology

Mark W. Womack Named to Bridgewest Perth Pharma Pty Ltd Board of Directors  (Miami and Perth, Australia, March 5, 2024) Bridgewest Perth Pharma, a global pharmaceutical supply and manufacturing company, with subsidiaries NovaCina and LumaCina, announced today the appointment of Mark W. Womack as a Director of the Board. “We are thrilled to have Mark

ADELAIDE, South Australia, and PERTH, Western Australia, Feb. 27, 2024 /PRNewswire/ — BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), and NovaCina Pty Ltd., a global fill-and-finish CDMO, announced a strategic partnership to provide integrated drug substance and drug product solutions for biologics developers. This alliance enables BioCina to offer the highest quality fill-and-finish solutions to

Adelaide, South Australia, November 6, 2023, BioCina Pty Ltd., a global end-to-end biologics contract development and manufacturing organization (CDMO), announced the expansion of their partnership with GPN Vaccines Ltd. GPN Vaccines is a biotechnology company developing a proprietary engineered whole-cell vaccine called Gamma-PNTM against Streptococcus pneumoniae. This bacterium is responsible for causing life-threatening infections such

ADELAIDE, Australia, Oct. 17, 2023 /PRNewswire/ — BioCina Pty Ltd., a global end-to-end biologics contract development and manufacturing organization (CDMO), announced a new partnership with GenomeFrontier Therapeutics AU Pty Ltd., the Australian entity of GenomeFrontier Therapeutics Inc. headquartered in Taiwan, for a project involving development of innovative virus-free chimeric antigen receptor T cell products (CAR-T)

A new partnership between The University of Western Australia and BioCina and LumaCina will benefit the Western Australian biomedical and health innovation sector. “UWA looks forward to working with BioCina and LumaCina to develop this incredibly important part of the WA economy, providing sovereign capability for manufacturing medicines to enable our community to live longer